Mumps disease in Beijing in the era of two-dose vaccination policy, 2005–2016

Abstract Background Since the introduction of mumps-containing vaccines (MuCV) in 1995 in Beijing, two-dose MuCV vaccination policy has been used, with the 1st and 2nd doses given at 18 months and 6 years of age, respectively. Methods Mumps epidemiology during 2005–2016 was described using surveillance data. Vaccine effectiveness (VE) of MuCV against disease was estimated for cases born during 2002–2009 and reported in 2016. VE against complications was estimated for all cases. MuCV coverage was estimated for children born during 1999–2015 using data from Beijing Immunization Information System. Results Overall mumps incidence decreased from 30.38/100,000 persons in 2005 to 10.26/100,000 persons in 2016. Incidence declines in children aged Conclusions Increasing MuCV coverage achieved declining mumps incidence and complication rate. Current epidemiology supported 2-dose MuCV vaccination policy. The incidence rise in persons aged 15–19 years in 2012 and waning immunity for the 2nd MuCV dose merited close follow-up.